Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Multi-kinase-IN-7

Catalog No. T213692 Copy Product Info
🥰Excellent
Multi-kinase-IN-7 is a multi-kinase inhibitor with IC50 values of 2.19, 2.95, 3.59, and 9.31 μM against EGFR, VEGFR2, TrKA, and CDK2, respectively. It demonstrates moderate to weak activity on FAK, AKT1, GSK3β, and CDK5, with IC50 values of 6.3, 9.2, 11.7, and 23.4 μM, respectively. Multi-kinase-IN-7 exhibits broad-spectrum antiproliferative potential against NCI cancer cell lines and can induce cell cycle arrest, apoptosis (apoptosis), and necrosis. MDA-MB-231 is applicable in breast cancer research.

Multi-kinase-IN-7

Copy Product Info
🥰Excellent
Catalog No. T213692

Multi-kinase-IN-7 is a multi-kinase inhibitor with IC50 values of 2.19, 2.95, 3.59, and 9.31 μM against EGFR, VEGFR2, TrKA, and CDK2, respectively. It demonstrates moderate to weak activity on FAK, AKT1, GSK3β, and CDK5, with IC50 values of 6.3, 9.2, 11.7, and 23.4 μM, respectively. Multi-kinase-IN-7 exhibits broad-spectrum antiproliferative potential against NCI cancer cell lines and can induce cell cycle arrest, apoptosis (apoptosis), and necrosis. MDA-MB-231 is applicable in breast cancer research.

Multi-kinase-IN-7
Pack SizePriceUSA StockGlobal StockQuantity
10 mgInquiryInquiryInquiry
50 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Multi-kinase-IN-7 is a multi-kinase inhibitor with IC50 values of 2.19, 2.95, 3.59, and 9.31 μM against EGFR, VEGFR2, TrKA, and CDK2, respectively. It demonstrates moderate to weak activity on FAK, AKT1, GSK3β, and CDK5, with IC50 values of 6.3, 9.2, 11.7, and 23.4 μM, respectively. Multi-kinase-IN-7 exhibits broad-spectrum antiproliferative potential against NCI cancer cell lines and can induce cell cycle arrest, apoptosis (apoptosis), and necrosis. MDA-MB-231 is applicable in breast cancer research.
Targets&IC50
EGFR:2.19 μM
In vitro
Multi-kinase-IN-7 (Compound 12b) exhibits broad-spectrum antiproliferative potential against NCI cancer cell lines at concentrations ranging from 0.01 to 100 μM over 24 hours, with an average GI50 of 10.63 μM. It shows significant antiproliferative activity specifically against all breast cancer cell lines, with GI50 values between 4.03 and 15.3 μM. At 15.3 μM over 48 hours, Multi-kinase-IN-7 induces cell cycle arrest at the G2/M phase in MDA-MB-231 cells and significantly promotes apoptosis (via the mitochondrial pathway) and necrosis.
Chemical Properties
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Multi-kinase-IN-7 | purchase Multi-kinase-IN-7 | Multi-kinase-IN-7 cost | order Multi-kinase-IN-7 | Multi-kinase-IN-7 in vitro